Monday, February 7, 1994
Jeffrey Casdin of Oppenheimer & Co. changed his rating on Amgen Inc. to "market performer" from "buy," following publication of the company's fourth quarter earnings. He said the renewed near-term growth of Epogen
erythropoietin isn't enough to overcome the uncertainty over the long-term growth of Neupogen
granulocyte colony stimulating factor. He recommended accumulation of shares at $40 and below.